Indication
Gastric hypersecretion with systemic mastocytosis
Gastric hypersecretion with systemic mastocytosis is a gastrointestinal complication of a rare hematologic neoplasm marked by the abnormal accumulation and activation of clonal mast cells within extracutaneous tissues. Read more about Gastric hypersecretion with systemic mastocytosis
502 drugs 204 manufacturers
Drugs that treat it
Common Gastric hypersecretion with systemic mastocytosis therapies.
PREVACID SOLUTAB (lansoprazole)
ACID REDUCER (FAMOTIDINE) (famotidine)
ACID REDUCER (FAMOTIDINE) (famotidine)
ACID REDUCER (FAMOTIDINE) (famotidine)
ACID REDUCER (FAMOTIDINE) (famotidine)
ACID REDUCER (FAMOTIDINE) (famotidine)
PREVACID 24HR (lansoprazole)
HEARTBURN RELIEF (FAMOTIDINE) (famotidine)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonGastric hypersecretion with systemic mastocytosis is a gastrointestinal complication of a rare hematologic neoplasm marked by the abnormal accumulation and activation of clonal mast cells within extracutaneous tissues.
This hypersecretory state occurs when systemic degranulation of mast cells releases excessive circulating histamine, which binds to histamine H2 receptors on gastric parietal cells to overstimulate hydrochloric acid production.
Clinically, affected individuals present with marked increases in basal acid output that predispose them to refractory peptic ulcer disease, erosive gastritis, duodenitis, acid-induced diarrhea, and upper gastrointestinal bleeding.
- merckmanuals.com
Gastric hypersecretion with systemic mastocytosis is a gastrointestinal complication of a rare hematologic neoplasm marked by the abnormal accumulation and activation of clonal mast cells within extracutaneous tissues
- nih.gov
Gastric hypersecretion with systemic mastocytosis is a gastrointestinal complication of a rare hematologic neoplasm marked by the abnormal accumulation and activation of clonal mast cells within extracutaneous tissues This hypersecretory state occurs when systemic degranulation of mast cells releases excessive circulating histamine, which binds to histamine H2 receptors on gastric parietal cells to overstimulate hydrochloric acid production Clinically, affected individuals present with marked in...
- ebi.ac.uk
This hypersecretory state occurs when systemic degranulation of mast cells releases excessive circulating histamine, which binds to histamine H2 receptors on gastric parietal cells to overstimulate hydrochloric acid production
- nih.gov
This hypersecretory state occurs when systemic degranulation of mast cells releases excessive circulating histamine, which binds to histamine H2 receptors on gastric parietal cells to overstimulate hydrochloric acid production Clinically, affected individuals present with marked increases in basal acid output that predispose them to refractory peptic ulcer disease, erosive gastritis, duodenitis, acid-induced diarrhea, and upper gastrointestinal bleeding
- fda.gov
Clinically, affected individuals present with marked increases in basal acid output that predispose them to refractory peptic ulcer disease, erosive gastritis, duodenitis, acid-induced diarrhea, and upper gastrointestinal bleeding
Personalize your experience
Follow Gastric hypersecretion with systemic mastocytosis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.